Ken Herrmann
Nuclear medicine leader who co-led VISION and runs one of the world's largest theranostics programmes.
Overview
Ken Herrmann was a lead investigator of VISION and of the German multicentre 177Lu-PSMA-617 registry, and leads the Essen theranostics centre that has treated thousands of patients with PSMA and somatostatin receptor radioligands. He has chaired the EANM oncology committee, co-authored the Lancet Oncology series on theranostics, and leads trials of alpha emitters and new targets such as FAP.
| Title | Journal | Year |
|---|---|---|
| Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer (VISION) | NEJM | 2021 |
| Radiotheranostics: a roadmap for future development | Lancet Oncology | 2020 |
Pages like this
not linked directly; found by shared links- PersonA. Oliver Sartor
Shares VISION, VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer, Lutetium-177 vipivotide tetraxetan, PSMA and the tag radioligand.
- PersonMichael J. Morris
Shares VISION, VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer, Lutetium-177 vipivotide tetraxetan, PSMA.
- PersonLouise Emmett
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters) and the tag radioligand.
- PersonUwe Haberkorn
Shares European Association of Nuclear Medicine, FAPI PET, FAP, Lutetium-177 vipivotide tetraxetan.
- InstitutionPostgraduate Institute of Medical Education and Research, Chandigarh
Shares FAPI PET, Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, PSMA PET.
- PairingPSMA PET → PSMA radioligand therapy
Shares VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer, Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET.
- InstitutionUniversity Hospital Düsseldorf / CIO Düsseldorf
Shares FAPI PET, FAP, Lutetium-177 vipivotide tetraxetan, PSMA.
- PersonJohannes Czernin
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).